The control of prostate-specific antigen expression and gene regulation by pharmacological agents

Pharmacological Reviews

Volumn 53, Issue 1, 2001, Pages 73-91

  Dixon, Shannon C ^a   Knopf, Kevin B ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; AGM 1883; AMG 1883; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANGIOGENESIS INHIBITOR; BUTYRIC ACID; BUTYRIC ACID DERIVATIVE; CALCITRIOL; DOCETAXEL; ESTRAMUSTINE; FINASTERIDE; FLAVOPIRIDOL; FUMAGILLOL CHLOROACETYLCARBAMATE; GALLIUM NITRATE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1; ISOBUTYRAMIDE; LEUPRORELIN; MESSENGER RNA; PC SPES; PHENYLACETIC ACID; PHENYLBUTYRIC ACID; PROSTATE SPECIFIC ANTIGEN; RESVERATROL; SURAMIN; THALIDOMIDE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CLINICAL TRIAL; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; REVIEW;

ANIMALS; DOWN-REGULATION; GENE EXPRESSION REGULATION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; RECEPTORS, ANDROGEN; UP-REGULATION;

EID: 0035101380     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (225)

1. Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7-ras tumors by sodium phenylacetate and tamoxifen combination
2. Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice
3. Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site
4. Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer
5. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma
6. p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells
7. Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer
8. Management of advanced prostate cancer
9. Phase II trial of gallium nitrate in previously treated patients with small cell lung cancer
10. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
11. Carboxyamidotriazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway
12. A pharmacokinetically guided phase II study of carboxyamido-triazole in androgen-independent prostate cancer
13. Mechanism of action and clinical uses of estramustine
14. Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate
15. Efficacy of the combination of nilutamide plus orchiectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1056 patients)
16. p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage
17. Multiple retinoid-responsive receptors in a single cell: Families of retinoid "X" receptors and retinoic acid receptors in the Xenopus egg
18. Finasteride dose-dependently reduces the proliferation rate of the LNCaP human prostatic cancer cell line in vitro
19. Identification of a second human retinoic acid receptor
20. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group
21. Regulation of PPARγ activity by mitogen-activated protein kinase
22. Sodium butyrate inhibits histone acetylation in cultured cells
23. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate
24. Epidemiologic evidence regarding predisposing factors to prostate cancer
25. Bcl-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor
26. Inhibition of ribonucleotide reductase by gallium in murine leukemic L1210 cells
27. Activity of retinoids against benzo-(A)pyrene-induced hyperplasia in mouse prostate organ cultures
28. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate-specific antigen is superior to all other clinical parameters
29. The glandular kallikrein family of enzymes: Tissue-specific expression and hormonal regulation
30. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter
31. Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells
32. Calcium-mediated signal transduction: Biology, biochemistry, and therapy
33. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone refractory prostate cancer
34. The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels
35. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
36. Phase II oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate
37. Androgen receptor activation in prostate tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor
38. The endocrinology and developmental biology of the prostate
39. Thalidomide is an inhibitor of angiogenesis
40. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid
41. Estramustine depolymerizes microtubules by binding to tubulin
42. Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells
43. A novel effect of genistein on androgen receptor and PSA expression in prostate cancer cells
44. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer
45. Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor viruses
46. Gosrelin acetate and flutamide versus bilateral orchiectomy: A phase III EORTC trial (30853)
47. The LAZ3/bcl-6 oncogene encodes a sequence-specific transcriptional inhibitor: A novel function for the BTB/POZ domain as an autonomous repressing domain
48. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer
49. Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells
50. In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3
51. Correlation of the osteoblastic phenotype with prostate-specific antigen expression in metastatic prostate cancer: Implications for paracrine growth
52. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
53. How effective is cytotoxic chemotherapy for disseminated prostatic carcinoma?
54. Chemotherapy for prostatic carcinoma
55. A critical assessment of the role of chemotherapy for endocrine-resistant prostatic carcinoma
56. Suramin, an active drug for prostate cancer: Interim observations in a phase I trial
57. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma
58. Phase I clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone refractory prostate cancer
59. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis
60. Induction of differentiation and apoptosis in the prostate cancer cell line LNCaP by sodium butyrate and galectin-1
61. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate
62. Specific inhibition of the activity of the urokinase receptor-mediated cell-surface plasminogen activation system by suramin
63. Characterization of a novel androgen sensitive, prostate specific antigen producing prostate carcinoma xenograft: LuCaP 23
64. Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, 1 alpha, 25 dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate
65. Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy
66. Suramin-induced differentiation of the human colon adenocarcinoma cell clone HT29-D4 in serum medium
67. The antiproliferative and antimetastatic compound L651582 inhibits muscarinic acetylcholine receptor-stimulated calcium influx and arachidonic acid release
68. Vitamin D: Metabolism and action
69. High dose intravenous estrogen therapy in advanced prostatic carcinoma: Use of serum prostate-specific antigen to monitor response
70. Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer
71. The in vitro response of four antisteroid receptor agents on the hormone-responsive prostate cancer cell line LNCaP
72. Resveratrol, a remarkable inhibitor of ribonucleotide reductase
73. 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte differentiation factor PPARγ
74. Reduction of serum prostate specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. A preliminary report
75. Effect of estramustine phosphate on the assembly of trypsin-treated microtubules and microtubules reconstituted from pure tubulin with either Tau, MAP2, or the tubulin-binding fragment of MAP2
76. Inhibition of angiogenesis by suramin
77. Carcinoma of the prostate
78. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors
79. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model
80. Age-related changes in tissue levels of prostatic acid phosphatase and prostate-specific antigen
81. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Group
82. Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate
83. Regulation of prostate-specific antigen gene expression in LNCaP human prostatic carcinoma cells by growth, dihydrotestosterone, and extracellular matrix
84. Phase I pharmacokinetic trial of intravenous (iv) estramustine phosphate (EMP) in patients with hormone refractory prostate cancer (HRPC)
85. Apoptosis and cell cycle effects induced by extracts of the Chinese herbal preparation PC-SPES
86. Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines LNCaP and LnCaP-r
87. Toxicity and antitumor activity of gallium nitrate and periodically related metal salts
88. Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3
89. Growth and cell survival following treatment with estramustine, nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145)
90. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion
91. Suramin, an anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A
92. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but down-regulate the prostatic acid phosphatase mRNA in the LNCaP cell line
93. LNCaP model of human prostatic carcinoma
94. Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor
95. Suramin binds to platelet-derived growth factor and inhibits its biological activity
96. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES
97. Induction of apoptosis and down-regulation of bcl-6 in Mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES
98. Effects of fenretinide (4-HPR) on prostate LNCaP cell growth, apoptosis, and prostate-specific gene expression
99. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines
100. Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha, 25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells
101. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ
102. Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone-refractory prostate cancer
103. Studies on prostate cancer. I. The effect of castration of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
104. The inhibition of receptor-mediated and voltage dependent calcium entry by the antiproliferative L-651,582
105. Stability of thalidomide in plasma
106. N-(4-hydroxyphenyl) retinamide induces cell cycle specific growth inhibition in PC3 cells
107. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth
108. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes
109. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial
110. Establishment and characterization of a human prostatic carcinoma cell line (PC-3)
111. The prevention of adipose differentiation of 3T3-L1 cells caused by retinoic acid is elicited through retinoic acid receptor alpha
112. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice
113. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275
114. Phase II evaluation of bolus gallium nitrate in lymphopreliferative disorders
115. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
116. Inhibition of prostatic tumor cell proliferation by suramin: Alterations in TGF-α-mediated autocrine growth regulation and cell cycle distribution
117. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
118. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
119. Androgen signal transduction and prostatic carcinoma
120. Indications for thalidomide therapy for leprosy
121. Angiogenesis: Role of calcium-mediated signal transduction
122. In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates
123. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines
124. Ligand for peroxisome proliferator-activated receptor γ (Troglitazone) has potent antitumor effects against human prostate cancer both in vitro and in vivo
125. 7Alpha-methyl-19-nortestosterone, a synthetic androgen with high potency: Structure-activity comparisons with other androgens
126. Potent anti-angiogenic action of AGM-1470: Comparison to the fumagillin parent
127. Effect of suramin on human prostate cancer cells in vitro
128. Cancer Statistics, 1999
129. Common pathway for tumor cell uptake of gallium-97 and iron-59 via a transferrin receptor
130. Inhibition of the effects of methylcholanthrene on mouse prostate in organ culture by vitamin A and its analogues
131. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone
132. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
133. Thalidomide and congenital abnormalities
134. Prostate specific antigen in hormonally-treated stage D2 prostate cancer: Is it always an accurate indicator of disease status?
135. 9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RxRα
136. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein
137. Exisulind induced apoptosis in prostate cancer cells is associated with down-regulation of androgen responsive elements
138. Retinoids as preventive and therapeutic anticancer agents
139. Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate
140. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer
141. Human androgen receptor binding to the androgen response element of prostate specific antigen
142. Nuclear reporter that identifies a novel retinoic acid response pathway
143. Thalidomide and congenital abnormalities
144. Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo
145. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells
146. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α, 25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines
147. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells
148. Inhibition of carcinogenesis by retinoids
149. Transformation of NIH/3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes down regulation of the fibroblast growth factor receptor: Reversal by suramin
150. Terminal differentiation of human breast cancer through PPARγ
151. Model systems of prostate cancer: Uses and limitations
152. Histone acetylation reduces nucleosome core particle linking number change
153. The treatment of hormone refractory prostate cancer
154. Antiproliferative effects of 1, 25-dihydroxyvitamin D3 on primary cultures of human prostatic cells
155. A human retinoic acid receptor which belongs to the family of nuclear receptors
156. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer
157. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate
158. The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells
159. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide
160. Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate
161. Prevention of primary prostate cancer in Lobund-Wistar rats by 4-hydroxyphenylretinamide
162. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer
163. Application of the MTT assay to human prostate cancer cell lines in vitro: Establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects
164. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate
165. Phenylacetate: A novel nontoxic inducer of tumor cell differentiation
166. Prostate-specific antigen changes before and after administration of an angiogenesis inhibitor (TNP-470)
167. Gallium nitrate in prostatic cancer: Evaluation of antitumor activity and effects on bone turnover
168. 1,25-Dihydroxy-16-ene-23-one-vitamin D3 and prostate cancer cell proliferation in vivo
169. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs
170. The evolving role of chemotherapy for muscle infiltrating bladder cancer
171. A phase II trial of gallium nitrate in patients with androgen-independent metastatic prostate cancer
172. The treatment of microsporideal diarrhea with thalidomide
173. Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)retinamide on prostate cancer cell growth and apoptosis
174. Effect of leuprorelin acetate on cell growth and prostate-specific antigen gene expression in human prostatic cancer cells
175. A reversed-phase high performance liquid chromatography method using solid-phase extraction to quantitate thalidomide in human serum
176. Hyperexpression of mitogen-activated protein kinase in human breast cancer
177. Vitamin D in prostate cancer: 1,25-Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
178. Actions of vitamin D3 analogs on human prostate cancer cell lines: Comparison with 1,25-dihydroxyvitamin D3
179. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system
180. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor
181. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)
182. Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy
183. Estramustine binds MAP-2 to inhibit microtubule assembly in vitro
184. Immunoperoxidase localization of prostate specific antigen
185. Suramin: An anti-cancer drug with a unique mechanism of action
186. Suramin and function of the adrenal cortex
187. Inhibition of proliferation and induction of differentiation in medulloblastoma- and astrocytoma-derived cell lines with phenylacetate
188. Isolation of a human prostate carcinoma cell line (DU 145)
189. Suramin interferes with interferon-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo
190. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells
191. Finasteride: The first 5α-reductase inhibitor
192. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia
193. Growth regulation of prostatic stromal cells by prostate-specific antigen
194. Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic acid phosphatase
195. Cytotoxicity of estramustine, a steroid-nitrogen mustard derivative, through non-DNA targets
196. Estramustine-a nitrogen mustard/steroid with microtubule activity
197. Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer
198. Total androgen ablation in the treatment of metastatic prostatic cancer
199. Treatment and survival of patients with cancer of the prostate
200. A 75% decline in prostate specific antigen (PSA) predicts survival in hormone refractory prostate cancer
201. A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer
202. Phase I study of phenylacetate administered twice daily to patients with cancer
203. Dendritic cells: Origin and differentiation
204. Chemoprevention of prostate cancer: The Prostate Cancer Prevention Trial
205. Gallium nitrate. A review of its pharmacological properties and therapeutic potential in cancer related to hypercalcemia
206. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
207. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor
208. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
209. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: High affinity for prostagenic and estrogenic steroids
210. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
211. In vitro activity of thalidomide against Mycobacterium avium complex
212. The differentiating agent phenylacetate increase prostate-specific antigen production by prostate cancer cells
213. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter of the PSA gene in LNCaP cells
214. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor
215. Salvage chemotherapy of advanced lymphoma with investigational drugs: Mitoguazone, gallium nitrate, and etoposide
216. Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines
217. Alteration of the phosphorylation state of p34(cdc2) kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity
218. Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo
219. Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro
220. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP
221. Antagonism of androgen action in prostate tumor cells by retinoic acid
222. 1α,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent